Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company focused on accelerating cancer drug development, has announced its plan to report first-quarter 2025 operating and financial results on May 15, 2025, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The webcast will be led by Panna Sharma, President and CEO, alongside other members of the management team. During the call, they will discuss the company’s financial performance and progress on upcoming milestones, clinical trials, and advancements in the RADR® AI and machine learning (ML) platform. Lantern Pharma is revolutionizing the field of oncology through its proprietary RADR® platform, which leverages over 100 billion data points and more than 200 advanced ML algorithms. This powerful tool helps identify drug candidates and patient populations most likely to benefit from these treatments, significantly reducing the time and cost of drug development. On average, Lantern's AI-driven drug programs move from initial insights to first-in-human clinical trials in just 2-3 years, with costs ranging between $1.0 million to $2.5 million per program. This is a stark contrast to traditional methods, which typically take longer and are more expensive. The company's current portfolio includes several drug candidates in various stages of clinical trials, targeting both solid tumors and blood cancers. One of its lead programs is a Phase 2 clinical trial, while others are in Phase 1. These trials are designed to evaluate the safety, efficacy, and optimal dosing regimens of the drugs, and positive outcomes could have significant implications for the treatment of cancer. Lantern has also formed a subsidiary, Starlight Therapeutics, dedicated to developing therapies for central nervous system (CNS) and brain cancers, an area with limited treatment options. The company estimates that its AI-driven pipeline of product candidates could potentially address a combined annual market of over $15 billion USD, offering life-changing therapies to a large number of cancer patients worldwide. In addition to its internal drug discovery programs, Lantern collaborates with world-class scientific advisors and researchers to enhance the capabilities and accuracy of the RADR® platform. These collaborations ensure that the company stays at the forefront of technological and scientific advancements in oncology. To attend the webcast, interested parties need to register in advance via the provided Zoom link. A replay of the earnings call will be available after the event on the investor relations section of the company's website: ir.lanternpharma.com. The forward-looking statements in this press release highlight the company's ambitions and potential challenges. Key risks include the uncertainty of securing future funding, the variability of clinical trial outcomes, and the regulatory approval process. Despite these hurdles, industry insiders recognize the transformative potential of Lantern's AI and ML technologies in oncology drug development. The ability to quickly and cost-effectively identify viable drug candidates and predict patient responses could significantly alter the landscape of cancer treatments, making it easier to bring new and more effective therapies to market. Lantern Pharma's commitment to leveraging AI and ML sets it apart in the biotech industry, where the integration of these technologies is still nascent but increasingly vital. With a strong management team and a robust scientific advisory board, the company is positioned to make substantial contributions to the field of oncology, potentially changing the lives of countless patients and generating significant economic value. For more information, visit www.lanternpharma.com or follow the company on LinkedIn and X (@lanternpharma).